8-K: Insmed Reports Positive 12-Month PAH Data for TPIP

Insmed announces positive 12-month safety and efficacy data from its open-label extension study of treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH).

Summary

• Insmed Incorporated announced positive 12-month data from its ongoing open-label extension (OLE) study of treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH).
• The data showed sustained improvement in secondary efficacy measures, including six-minute walk distance (6MWD), N-terminal fragment pro-B-type natriuretic peptide (NT-proBNP) concentration, and World Health Organization (WHO) Functional Class.
• Patients who switched from placebo to TPIP in the OLE study demonstrated similar clinical benefits to those who continued TPIP treatment.
• TPIP was found to be safe and well-tolerated, with no newly identified safety signals observed through 12 months, even at doses up to 1,280 mcg once daily.
• These results support the continued clinical development of TPIP, including the ongoing Phase 3 PALM-PAH study.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive development, with robust 12-month data reinforcing TPIP's potential as a best-in-class therapy for PAH and supporting its advancement into Phase 3 trials.

Positives

• Sustained improvement in six-minute walk distance (6MWD) by +55.7 meters for the TPIP Continued group and +54.1 meters for the Placebo Crossed group at 12 months.
• Approximately 60% reduction in NT-proBNP concentration in both TPIP Continued and Placebo Crossed groups.
• 80.6% of patients in the Placebo Crossed group and 78.3% in the TPIP Continued group achieved WHO Functional Class I or II by Month 12.
• Clinically meaningful improvement in REVEAL Lite 2.0 score, with a mean improvement of 2.0 points for the TPIP Continued group and 1.4 points for the Placebo Crossed group.
• Approximately 65% of all patients achieved Refined Low Risk status, associated with a less than 5% estimated risk of mortality at three years.
• TPIP was generally well-tolerated with no newly identified safety signals through 12 months.
• Doses up to 1,280 mcg once daily were permitted in the OLE study.
• 91% of OLE patients remained on TPIP at Month 12.

Negatives

• Treatment-emergent adverse events (TEAEs) occurred in 89.0% of patients.
• Serious TEAEs were observed in 18.7% of patients.
• Severe TEAEs were observed in 16.5% of patients.
• TEAEs leading to study discontinuation were experienced by 7.7% of patients.
• Four deaths occurred, though none were considered related to TPIP treatment.
• The most common TEAEs included headache (28.6%), cough (15.4%), and nasopharyngitis (14.3%).

Risks

• The risk that full data sets from the OLE study or future clinical trials will not be consistent with interim results.
• The risk that OLE study data, being open-label, may not be predictive of results from the Phase 3 randomized, placebo-controlled trial.
• The risk that secondary and exploratory efficacy endpoints may overestimate the true treatment effect.
• Potential failure to successfully conduct future clinical trials, including enrollment or retention issues.
• Development of unexpected safety or efficacy concerns related to TPIP.
• Failure of third parties to manufacture TPIP or conduct clinical trials.
• Failure to obtain regulatory approval for TPIP.
• Inaccuracies in market size estimates or patient uptake, adherence, or discontinuation rates.

Future Outlook

The company is advancing its Phase 3 PALM-PAH study and plans to publish the 12-month OLE study results in the future. Initiation of Phase 3 trials for PH-ILD is expected in 2H:26, and for IPF and PPF in 1H:27.

Management Comments

• "These data from our ongoing OLE study with TPIP represent an important milestone in our efforts to fully harness the potential of treprostinil and provide meaningful benefit to patients with pulmonary arterial hypertension."
• "These data, coupled with the statistically significant and clinically meaningful results from our Phase 2b randomized study, demonstrate TPIP's potential to become the prostanoid of choice for PAH patients, and we remain excited to be advancing our Phase 3 PALM-PAH study."
• "The REVEAL Lite 2.0 risk score provides a powerful, non-invasive way to track disease trajectory. Previous REVEAL Lite 2.0 validation showed that a 1-point score improvement reduces risk of mortality by 23% and reduces the risk of clinical worsening by 21%. Here we saw that patients on TPIP averaged a greater than 1-point improvement from baseline, which is really meaningful for patients. Sustained improvements of this magnitude, alongside gains in exercise capacity and Functional Class, provide a strong clinical rationale to advance this therapy into Phase 3 development."
• "These Results, Combined with Once-Daily Inhaled Profile, Reinforce TPIPs Potential to Become the Prostanoid of Choice."
• "Sustained improvements for patients remaining on TPIP and comparable benefits for patients who switched from placebo."
• "TPIP treatment led to meaningful reductions from baseline in REVEAL Lite 2.0 scores, a validated mortality risk assessment tool."
• "TPIP continued to demonstrate a favorable safety & tolerability profile with a low rate of cough (15%*, of which 85% was classified as mild)."

Industry Context

StockSavvy.ai notes that the positive 12-month data for TPIP in PAH, demonstrating sustained efficacy and a favorable safety profile, positions it as a potential leading prostanoid therapy. The comparable outcomes for patients switching from placebo to TPIP are particularly encouraging, suggesting a strong treatment effect. The advancement into Phase 3 trials across multiple indications (PAH, PH-ILD, IPF, PPF) indicates a strategic expansion by Insmed in the respiratory and rare disease space.

Comparison to Industry Standards

• The mean improvement in 6MWD of +55.7 meters for the TPIP Continued group and +54.1 meters for the Placebo Crossed group at 12 months compares favorably to other prostanoid therapies. For instance, the Phase 2b study of TPIP showed a placebo-adjusted improvement of +35.5 meters at Week 16.
• The ~60% reduction in NT-proBNP concentration observed in both OLE groups is a significant biomarker improvement. The Phase 2b study reported a placebo-adjusted reduction of ~60% at Week 16.
• Approximately 80% of patients achieving WHO Functional Class I or II by Month 12 in the OLE study indicates a substantial improvement in patient functional status, aligning with or exceeding results from other PAH treatments.
• The mean REVEAL Lite 2.0 score improvement of 2.0 points (TPIP Continued) and 1.4 points (Placebo Crossed) is clinically meaningful, as a 1-point improvement is associated with a ~23% reduction in mortality risk.
• The achievement of Refined Low Risk status by ~65% of patients is a strong indicator of improved long-term prognosis, a key benchmark in PAH management.
• Compared to other inhaled treprostinil therapies, TPIP's once-daily administration offers a significant convenience advantage, potentially improving patient adherence and outcomes.

Stakeholder Impact

• Shareholders: Positive data may lead to increased confidence and potential stock price appreciation, supporting the company's development pipeline.
• Patients with PAH: The sustained efficacy and favorable safety profile of TPIP offer hope for improved disease management and quality of life.
• Healthcare Providers: The data provide further clinical rationale for considering TPIP as a treatment option, especially given its once-daily administration.
• Insurers/Payers: Positive Phase 3 data will be crucial for securing reimbursement and market access for TPIP.

Next Steps

• Continue Phase 3 PALM-PAH study for TPIP in PAH.
• Initiate Phase 3 trials for TPIP in PH-ILD (expected 2H:26).
• Initiate Phase 3 trials for TPIP in IPF and PPF (expected 1H:27).
• Publish the 12-month OLE study results in the future.

Key Dates

Recommendation

The 12-month OLE data for TPIP in PAH are highly encouraging, demonstrating sustained efficacy and a favorable safety profile, with comparable results for patients switching from placebo. This reinforces TPIP's potential as a best-in-class therapy and supports the company's strategic expansion into Phase 3 trials across multiple indications. The strong clinical rationale and positive trajectory warrant a strong buy recommendation.

Keywords

Pulmonary Arterial Hypertension, TPIP, Treprostinil Palmitil Inhalation Powder, Insmed, OLE Study, PAH Treatment, Clinical Trial Data, Biopharmaceutical